ATRX and pituitary adenocarcinoma: A multicenter study by Casar-Borota et al. [49] analyzed a large cohort of aggressive pituitary tumors and pituitary carcinomas, including 22 corticotroph tumors, and found that ATRX loss-of-function mutations were present in 19% of cases, with a higher prevalence among corticotroph tumors (32%) compared to other PitNET subtypes.